Navigation Links
Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Date:3/28/2008

al wanted to equip a new lab with all three technologies, they would have to acquire three separate consoles, each with a different measurement modality, training requirements and data storage protocols. The Volcano s5i can now accommodate the three primary intravascular diagnostic tools in regular use by cardiologists today (high frequency rotational IVUS, fast and simple phased array IVUS, and pressure-based FFR guidewires) on a single platform, making modern day imaging consoles more flexible than ever before.

Joe Burnett, associate vice president of marketing for Volcano, said, "We believe that IVUS is one of the fastest growing market segments in interventional cardiology today. Our internal market model suggests that worldwide IVUS revenue grew approximately 15% in 2007. More and more physicians are augmenting their daily interpretation of angiography with this more exacting, precise technology. IVUS and FFR can provide objective measurements of lesion severity and stent expansion, thus removing some of the inherent guess work surrounding 2D x-ray images. We believe that having these modalities available on a single integrated system can only further adoption of these important therapy guidance tools."

Training and Education

As part of the s5-Revo and s5-FFR market introduction, Volcano is also launching Volcano TLC, a comprehensive on-site education program available to current and future Volcano customers, targeted to increase IVUS and FFR awareness and build staff proficiency with these new integrated systems. Volcano TLC (Training and Learning Clinics) offers a combination of keynote speaker presentations, physician proctorships, hands-on system training, guided proficiency tools and workflow troubleshooting, all designed to leverage modern-day IVUS and FFR technology, and to allow physicians to acquire these precise diagnostic measurements in less time than ever before.

To kick-off the Volcano TLC program, John McB. Hodgson, M.
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...onal carbon layer in which the carbon atoms are ar...omb. Carbon nanotubes are rolled-up sheets of grap...hite. Graphene boasts some very special characteri...t thermal conductor, and reconciles such conflicti...tion, graphene is impermeable to gases, which make...
(Date:11/23/2009)...wire-FirstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;T...dentifiesandadvancesadiverseportfolioofpromisingca...odayreportedthatCytopia(ASX:CYT)hascommencedenroll...ly-administeredJAK1/JAK2inhibitor.Thetrialisbeingc...ltomergeCytopiaintoYMhasbeenpreviouslyannouncedand...
(Date:11/23/2009)...uo;s Sporicidin disinfectant solution and wipes ar...nts against H1N1 and Influenza A., , ...009 -- Contec Inc, the leading manufacturer of cl...icidin disinfectants have been deemed by the EPA ...uding Pandemic 2009 H1N1 influenza A virus (the sw...
(Date:11/23/2009).../-InimexPharmaceuticals,Inc.announcedtodaythatitha.... ,, Abramsbringsmorethan25yearsofdrugdiscovery...fthenuclearmedicineimagingagent,Cardiolite,andwork...ger,BiomedicalResearchWorldwide.In1996,Abramsledth...andCEOfrom1996to2006.AnorMEDdiscoveredanddeveloped...
Breaking Biology Technology:Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2Inimex Announces Appointment of New CEO 2
...OKYO, Japan, April 28 HOYA Corporation today,anno...n for the period,ended March 31, 2008, a 36.5% inc...rating income for the quarter was 18.0 billion yen...in the prior year period. Net,income for the fourt...are,were 37.71 yen. For the same quarter of the pr...
... Vaccine for new strain of virus broadens governme... France, April 28 ,Sanofi Pasteur, the vaccines di...at the U.S. Department of Health and Human Service...produce approximately 38.5 million,doses of vaccin...za. Sanofi,Pasteur has a multi- year contract with...
...ANJING, CHINA, April 28 Simcere,Pharmaceutical Gr...lier of,branded generic pharmaceuticals and manufa... Endu in China, today announced that it has been,i... Good Management,Limited, a British Virgin Islands...luding certain senior management of Simcere Pharma...
Other Biology Technology:Hoya Announces Fourth Quarter and FY2007 Financial Results 2Hoya Announces Fourth Quarter and FY2007 Financial Results 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3
(Date:11/23/2009)...controvertible evidence" that the volcanic super-e...000 years ago deforested much of central India, so...ort. , The volcano ejected an estimated 800 cubi... crater (now the world,s largest volcanic lake) th...Ash from the event has been found in India, the In...
(Date:11/23/2009)...sity of Alabama at Birmingham (UAB) researchers sh...ical conditions (co-morbidity) do not explain the ...s compared to Caucasians who also have colon cance...r , a journal of the American Cancer Society. , ...bidity are independent predictors of poor survival...
(Date:11/23/2009)...ries about the multiple health benefits of vitamin...ient, increased awareness of the huge numbers of p...d even led to an appreciation of it as "nature,s a...of your immune system to prevention of heart disea...is now seen as one of the most critical nutrients ...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Par Pharmaceutical Receives Final Approval To Market Generic Starlix 28R 29 56816 1Par Pharmaceutical Receives Final Approval To Market Generic Starlix 28R 29 56816 2SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 1SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 2SRI Internationals Research on Nicotine Use and Dependence Featured in the National Cancer Institutes Tobacco Control Monograph Series 56811 3FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL 13986 1FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL 13986 2
...al Center have identified a previously unknown fam...esponsible for the plague especially efficient at ...nly demonstrated that the use of the common roundw... Yersinia pestis, the bacterium that causes plague... pestis and the worm is quite similar to what occu...
...ege are using tobacco plants to produce monoclonal...t can target and hunt down cancer cells. The plant...roducing anticancer antibodies, raising hopes that...cientists, led by Hilary Koprowski, M.D., professo...he Biotechnology Foundation Laboratories and the C...
...have made significant new advances in determining ...covery that in one sense takes up where Watson and...e-helical structure of this biological blueprint f...hemistry is to predict the structure of a molecule...he "Holy Grail" of protein chemistry. , Today, th...
Other Biology News:Novel plague virulence factor identified 2Novel plague virulence factor identified 3Novel plague virulence factor identified 4Scientists turn tobacco against cancer 2Major advance made on DNA structure 2Major advance made on DNA structure 3
21-mer duplex from B-Bridge International
...s the first fully genetically encoded fluorescent ...acellular hydrogen peroxide (H2O2), one of the mai...f yellow fluorescent protein inserted into the reg...xyR-RD), HyPer demonstrates submicromolar affinity...
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
Luminex 100 Instrument System from Upstate
Biology Products: